Element Biosciences announced Vitari, a new high‑throughput sequencing platform that the company says can produce roughly 3 terabytes per run and sequence a 30X human genome for $100 in 36 hours. The company positions Vitari as a cost‑disruptive option for large‑scale genomic programs and spatial/transcriptomics workloads, pitching per‑sample economics and throughput as levers to expand genomic adoption. Early commercial availability, run‑cost assumptions and third‑party validations will determine market uptake; the platform’s price‑performance claim will likely spur head‑to‑head benchmarking with incumbent high‑throughput sequencers. Labs and customers will monitor reagent costs, instrument uptime and bioinformatics pipelines supporting high‑volume use.